
|Videos|October 21, 2022
Enfortumab Vedotin (EV) Monotherapy and Pembrolizumab (P) Combination Treatments in Urothelial Cancer
Arlene Siefker-Radtke, MD, opens a discussion recapping the ESMO 2022 conference surrounding advanced and metastatic urothelial cancer.
Advertisement
Episodes in this series

Now Playing
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Trump Announces Deals With Lilly, Novo to Cut Weight Loss Drug Prices
2
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
3
Ritlecitinib Shows Significant Reduction in Alopecia Areata Psychosocial Burden
4
Adolescents, Young Adults Use AI Chatbots for Mental Health Advice
5














































